ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Relmada Announces Outcome of FDA Meeting for Major Depressive Disorder Treatment
June 02, 2020Relmada Therapeutics announced the completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its development program of REL-1017 (dextromethadone) for the adjunctive treatment of major depressive disorder (MDD) patients.
Pharma Sources Insight January 2025
